KAMADA LTD (KMDA)
IL0010941198 - Common Stock
Overall KMDA gets a fundamental rating of 5 out of 10. We evaluated KMDA against 588 industry peers in the Biotechnology industry. KMDA has a medium profitability rating, but doesn't score so well on its financial health evaluation. KMDA has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
KMDA had positive earnings in the past year.
KMDA had a positive operating cash flow in the past year.
In multiple years KMDA reported negative net income over the last 5 years.
Of the past 5 years KMDA 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 2.33%, KMDA belongs to the top of the industry, outperforming 94.86% of the companies in the same industry.
With an excellent Return On Equity value of 3.39%, KMDA belongs to the best of the industry, outperforming 95.03% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 2.60%, KMDA belongs to the top of the industry, outperforming 95.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.33% | ||
| ROE | 3.39% | ||
| ROIC | 2.6% |
ROA(3y)0.31%
ROA(5y)4.38%
ROE(3y)0.28%
ROE(5y)5.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 5.81%, KMDA belongs to the best of the industry, outperforming 95.55% of the companies in the same industry.
In the last couple of years the Profit Margin of KMDA has declined.
KMDA's Operating Margin of 7.06% is amongst the best of the industry. KMDA outperforms 94.86% of its industry peers.
KMDA's Operating Margin has declined in the last couple of years.
The Gross Margin of KMDA (38.94%) is better than 79.28% of its industry peers.
KMDA's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.06% | ||
| PM (TTM) | 5.81% | ||
| GM | 38.94% |
OM growth 3Y-21.17%
OM growth 5Y-15.97%
PM growth 3Y-23.21%
PM growth 5Y-21.48%
GM growth 3Y2.9%
GM growth 5Y1.44%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so KMDA is destroying value.
KMDA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, KMDA has more shares outstanding
Compared to 1 year ago, KMDA has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.36 indicates that KMDA is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of KMDA (2.36) is better than 73.97% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that KMDA is not too dependend on debt financing.
KMDA's Debt to Equity ratio of 0.03 is in line compared to the rest of the industry. KMDA outperforms 41.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.36 |
ROIC/WACC0.29
WACC8.9%
2.3 Liquidity
A Current Ratio of 3.43 indicates that KMDA has no problem at all paying its short term obligations.
KMDA has a Current ratio of 3.43. This is in the lower half of the industry: KMDA underperforms 61.30% of its industry peers.
A Quick Ratio of 1.64 indicates that KMDA should not have too much problems paying its short term obligations.
The Quick ratio of KMDA (1.64) is worse than 79.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.43 | ||
| Quick Ratio | 1.64 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 400.00% over the past year.
KMDA shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -22.88% yearly.
The Revenue has grown by 10.18% in the past year. This is quite good.
The Revenue has been growing slightly by 4.48% on average over the past years.
EPS 1Y (TTM)400%
EPS 3Y-27.28%
EPS 5Y-22.88%
EPS growth Q2Q28.57%
Revenue 1Y (TTM)10.18%
Revenue growth 3Y2.28%
Revenue growth 5Y4.48%
Revenue growth Q2Q-19.82%
3.2 Future
The Earnings Per Share is expected to grow by 50.37% on average over the next years. This is a very strong growth
Based on estimates for the next years, KMDA will show a quite strong growth in Revenue. The Revenue will grow by 14.81% on average per year.
EPS Next Y53%
EPS Next 2Y67.99%
EPS Next 3Y50.37%
EPS Next 5YN/A
Revenue Next Year10.02%
Revenue Next 2Y16.47%
Revenue Next 3Y14.81%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 34.33, KMDA can be considered very expensive at the moment.
Based on the Price/Earnings ratio, KMDA is valued cheaper than 95.38% of the companies in the same industry.
When comparing the Price/Earnings ratio of KMDA to the average of the S&P500 Index (24.84), we can say KMDA is valued slightly more expensively.
A Price/Forward Earnings ratio of 22.44 indicates a rather expensive valuation of KMDA.
Based on the Price/Forward Earnings ratio, KMDA is valued cheaper than 96.23% of the companies in the same industry.
KMDA's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.35.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.33 | ||
| Fwd PE | 22.44 |
4.2 Price Multiples
KMDA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. KMDA is cheaper than 97.26% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.06 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
KMDA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as KMDA's earnings are expected to grow with 50.37% in the coming years.
PEG (NY)0.65
PEG (5Y)N/A
EPS Next 2Y67.99%
EPS Next 3Y50.37%
5. Dividend
5.1 Amount
No dividends for KMDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
KAMADA LTD
NASDAQ:KMDA (4/26/2024, 7:00:06 PM)
5.15
-0.05 (-0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap295.97M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 34.33 | ||
| Fwd PE | 22.44 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.65
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.33% | ||
| ROE | 3.39% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 7.06% | ||
| PM (TTM) | 5.81% | ||
| GM | 38.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.03 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.43 | ||
| Quick Ratio | 1.64 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)400%
EPS 3Y-27.28%
EPS 5Y
EPS growth Q2Q
EPS Next Y53%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)10.18%
Revenue growth 3Y2.28%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y